Your browser doesn't support javascript.
loading
Omega-3 supplementation associated with improved parent-rated executive function in youth with mood disorders: secondary analyses of the omega 3 and therapy (OATS) trials.
Vesco, Anthony T; Young, Andrea S; Arnold, L Eugene; Fristad, Mary A.
Afiliação
  • Vesco AT; Department of Psychiatry, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
  • Young AS; Division of Child & Adolescent Psychiatry, Johns Hopkins University, Baltimore, MD, USA.
  • Arnold LE; Department of Psychiatry and Behavioral Health, Ohio State University, Columbus, OH, USA.
  • Fristad MA; Department of Psychiatry and Behavioral Health, Ohio State University, Columbus, OH, USA.
J Child Psychol Psychiatry ; 59(6): 628-636, 2018 06.
Article em En | MEDLINE | ID: mdl-29063592
ABSTRACT

BACKGROUND:

Improvements in executive functioning (EF) may lead to improved quality of life and lessened functional impairment for children with mood disorders. The aim was to assess the impact of omega-3 supplementation (Ω3) and psychoeducational psychotherapy (PEP), each alone and in combination, on EF in youth with mood disorders. We completed secondary analyses of two randomized controlled trials (RCTs) of Ω3 and PEP for children with depression and bipolar disorder.

METHODS:

Ninety-five youths with depression or bipolar disorder not otherwise specified/cyclothymic disorder were randomized in 12-week RCTs. Two capsules (Ω3 or placebo) were given twice daily (1.87 g Ω3 total daily, mostly eicosapentaenoic acid). Families randomized to PEP participated in twice-weekly 50-min sessions. Analyses assess impact of interventions on the Behavior Rating Inventory of Executive Functioning (BRIEF) parent-report Global Executive Composite (GEC) and two subscales, Behavior Regulation (BRI) and Metacognition (MI) Indices. Intent-to-treat repeated measures ANOVAs, using multiple imputation for missing data, included all 95 randomized participants. Trials were registered with www.clinicaltrials.gov, NCT01341925 & NCT01507753.

RESULTS:

Participants receiving Ω3 (aggregating combined and monotherapy) improved significantly more than aggregated placebo on GEC (p = .001, d = .70), BRI (p = .004, d = .49), and MI (p = .04, d = .41). Ω3 alone (d = .49) and combined with PEP (d = .67) each surpassed placebo on GEC. Moderation by attention-deficit/hyperactivity disorder (ADHD) comorbidity was nonsignificant although those with ADHD showed nominally greater gains. PEP monotherapy had negligible effect.

CONCLUSIONS:

Decreased impairment in EF was associated with Ω3 supplementation in youth with mood disorders. Research examining causal associations of Ω3, EF, and mood symptoms is warranted.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psicoterapia / Transtorno Bipolar / Ácidos Graxos Ômega-3 / Avaliação de Resultados em Cuidados de Saúde / Transtorno Depressivo / Função Executiva / Autocontrole / Metacognição Tipo de estudo: Clinical_trials / Risk_factors_studies Limite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: J Child Psychol Psychiatry Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psicoterapia / Transtorno Bipolar / Ácidos Graxos Ômega-3 / Avaliação de Resultados em Cuidados de Saúde / Transtorno Depressivo / Função Executiva / Autocontrole / Metacognição Tipo de estudo: Clinical_trials / Risk_factors_studies Limite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: J Child Psychol Psychiatry Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos